T-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review

Jessica W.Y. Wu, Sudiksha Dand, Lachlan Doig, Anthony T. Papenfuss, Clare L. Scott, Gwo Ho, Joshua D. Ooi

Research output: Contribution to journalReview ArticleResearchpeer-review

32 Citations (Scopus)


Ovarian cancer, in particularly high-grade serous ovarian cancer (HGSOC) and ovarian carcinosarcoma (OCS), are highly aggressive and deadly female cancers with limited treatment options. These tumors are generally unresponsive to immune check-point inhibitor (ICI) therapy and are referred to as immunologically “cold” tumors. Cell-based therapy, in particular, adoptive T-cell therapy, is an alternative immunotherapy option that has shown great potential, especially chimeric antigen receptor T cell (CAR-T) therapy in the treatment of hematologic malignancies. However, the efficacy of CAR-T therapy in solid tumors has been modest. This review explores the potential of another cell-based therapy, T-cell receptor therapy (TCR-T) as an alternate treatment option for immunological “cold” OC and OCS tumors.

Original languageEnglish
Article number672502
Number of pages8
JournalFrontiers in Immunology
Publication statusPublished - 13 Apr 2021


  • cell-based therapy
  • immunotherapy
  • ovarian cancer
  • T-cell receptor
  • tumor neoantigen

Cite this